Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

A strategic new addition
September 2020
SHARING OPTIONS:

NEW YORK—Lucid Diagnostics Inc., a majority-owned subsidiary of PAVmed Inc., has expanded its team with the addition of Stanley Lapidus as its new strategic advisor. Lapidus, founder and former chairman and CEO of Exact Sciences, will help to support Lucid’s commercial, regulatory, clinical trial and capital markets strategies.
 
“I am thrilled to welcome Stan Lapidus as a Lucid strategic advisor and look forward to tapping into his vast wealth of knowledge, experience and wisdom as we advance EsoGuard and EsoCheck commercialization ... Since its inception, Lucid’s stated goal has been for its early detection technologies to have as great an impact on preventing esophageal cancer as widespread Pap testing has had in preventing cervical cancer. We are fortunate that one of the most impactful persons in preventing deaths from cervical cancer will be helping us achieve this mission,” said Dr. Lishan Aklog, PAVmed’s chairman and CEO and Lucid’s executive chairman.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.